GlobeNewswire: Amarin Corporation plc Contains the last 10 of 465 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:49:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2851545/0/en/Research-Evaluating-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-American-College-of-Cardiology-s-ACC-Annual-Scientific-Session-Expo.html?f=22&fvtc=4&fvtv=14393Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo2024-03-25T12:00:00Z<![CDATA[-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.]]>https://www.globenewswire.com/news-release/2024/02/29/2837827/0/en/Amarin-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=14393Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update2024-02-29T12:00:00Z<![CDATA[-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million -- -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million ---- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 ---- Company to Host Conference Call Today at 8:00 a.m. EDT --DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.]]>https://www.globenewswire.com/news-release/2024/02/15/2829894/0/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html?f=22&fvtc=4&fvtv=14393Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 20242024-02-15T13:00:00Z<![CDATA[DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A.]]>https://www.globenewswire.com/news-release/2024/01/22/2812941/0/en/Amarin-Chairman-CEO-Issue-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=14393Amarin Chairman & CEO Issue Letter to Shareholders2024-01-22T12:30:00Z<![CDATA[DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders:]]>https://www.globenewswire.com/news-release/2024/01/10/2806970/0/en/Amarin-Provides-Preliminary-Fourth-Quarter-2023-Selected-Financials-and-Outlines-Key-Priorities-For-2024.html?f=22&fvtc=4&fvtv=14393Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 20242024-01-10T12:00:00Z<![CDATA[-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 ---- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million --]]>https://www.globenewswire.com/news-release/2023/12/11/2793825/0/en/Amarin-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=14393Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference2023-12-11T13:00:00Z<![CDATA[DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.]]>https://www.globenewswire.com/news-release/2023/11/12/2778635/0/en/New-REDUCE-IT-Analyses-Show-VASCEPA-icosapent-ethyl-Associated-with-29-Percent-Relative-Risk-Reduction-Compared-with-Placebo-in-Prespecified-Subgroup-of-Patients-with-Metabolic-Syn.html?f=22&fvtc=4&fvtv=14393New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline2023-11-12T14:00:00Z<![CDATA[-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo ---- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --]]>https://www.globenewswire.com/news-release/2023/11/01/2770981/0/en/Amarin-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=14393Amarin Reports Third Quarter 2023 Financial Results2023-11-01T11:00:00Z<![CDATA[-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million --]]>https://www.globenewswire.com/news-release/2023/10/31/2770478/0/en/Amarin-Appoints-Jonathan-Provoost-Executive-Vice-President-Chief-Legal-Compliance-Officer.html?f=22&fvtc=4&fvtv=14393Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer2023-10-31T16:00:00Z<![CDATA[-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin --DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15.]]>https://www.globenewswire.com/news-release/2023/10/26/2767462/0/en/Latest-Research-Evaluating-VASCEPA-VAZKEPA-icosapent-ethyl-and-Subgroups-from-the-REDUCE-IT-Landmark-Outcomes-Trial-to-be-Presented-at-the-American-Heart-Association-AHA-Scientific.html?f=22&fvtc=4&fvtv=14393Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 20232023-10-26T12:00:00Z<![CDATA[-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting --]]>